Disclaimer
The report contains forward-looking statements, which may be identi ed by their use of words like plans, expects, will, anticipates, believes, intends, projects, estimates or other words of similar meaning. All statements that address expectations or projections about the future, including but not limited to statements about the companys strategy for growth, product development, market position, expenditures, and nancial results, are forward-looking statements. Forwardlooking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The Companys actual results, performance or achievements could thus differ materially from those projected in any such forward looking-statements. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events.
Contents
Corporate Identity 03 Financial Progress 04 Highlights, 2012-13 14 Chairmans Message 16 Global Generics 20 Analysis of Financial Statements 21 Risk Management 24 Directors Report 27 Report on Corporate Governance 34 Standalone Financial Statements 42 Consolidated Financial Statements 71 Corporate Information 87
business, convinced that either we took control of it our destiny or someone else would. The result is evident in the numbers.
In a challenging 2012-13, the evolution was most distinctly visible, as we grew revenues by about 4% and PAT by 27% over the previous year.
The last three years have been seminal in the history of Alembic. The Company extended from Generalised therapies to Speciality therapeutic segments and launched aligned portfolios.
Launched new therapeutic divisions. Widened its regulated markets coverage. Increased product complexity. Increased the proportion of speciality products. Climbed the ling value-chain (Para III to Para IV and Para IV FTFs in the US). Doubled its API basket. Streamlined systems and processes. Strengthened its people management. The results have been explained in the following pages.
10.23%
EBIDTA margin, 2009-10
16.79%
EBIDTA margin, 2012-13
2 Alembic Pharmaceuticals Limited
Vision
To become a knowledgedriven global pharmaceutical company with the highest level of operational excellence in all spheres
Mission
To provide access to the best healthcare products at affordable prices to everyone, present anywhere in the world.
Assuming control is good for the Company, for the shareholder and every stakeholder
Business
Revenue (` lac)
151,725
EBIDTA (` lac)
25,589
146,235
120,205
22,085
113,814
16,033
11,688
2010-11
2011-12
2012-13
2010-11
2011-12
2012-13
3,954
2010-11
8,539 EBIDTA growth 2009-10* Net prot growth CAGR over 3 years Over 2011-12 2011-12 CAGR over 3 years
2009-10*
Revenue growth
2009-10*
13,013
Business progression
Profitability
EBIDTA margin (%)
16.79
ROE (%)
33.41
ROCE (%)
31.40 9.72 2010-11 20.75 2011-12 24.72 2009-10* ROCE growth
15.06
13.34
10.23
7.10
8.87
2010-11
2011-12
2012-13
3.46
2010-11
2011-12
2012-13
11.69
2010-11
28.92
2011-12
2012-13
33.30
2009-10*
2009-10*
2009-10*
ROE growth
* Financial year 2009-10 numbers reect those of the erstwhile Alembic Limited, whereas for the subsequent years (2010-11 onwards) the numbers reect the impact of the demerged Alembic Pharmaceuticals Limited.
2012-13
Building a US presence
Alembic resolved to grow its US presence with the objective to graduate from being just another pharmaceutical player to a globally recognised organisation.
Shift